Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis.

Best M, Molinari N, Chasset F, Vincent T, Cordel N, Bessis D.

Acta Derm Venereol. 2019 Mar 1;99(3):256-262. doi: 10.2340/00015555-3091.

2.

Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.

Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, Rosen A, Casciola-Rosen L.

Arthritis Rheum. 2013 Nov;65(11):2954-62. doi: 10.1002/art.38093.

3.

Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report.

Kubeček O, Soukup T, Paulík A, Kopecký J.

BMC Cancer. 2016 Aug 25;16(1):684. doi: 10.1186/s12885-016-2715-1.

4.

Small cell lung cancer and interstitial pneumonia associated with anti-transcriptional intermediary factor-1γ-positive dermatomyositis.

Kato T, Ito S, Tsuzuki T, Watanabe D, Kubo A, Yamaguchi E.

Respirol Case Rep. 2019 Mar 12;7(4):e00412. doi: 10.1002/rcr2.412. eCollection 2019 May.

5.

Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis.

Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L.

J Am Acad Dermatol. 2015 Mar;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009. Epub 2015 Jan 14.

6.

Autoantibody to transcriptional intermediary factor-1β as a myositis-specific antibody: clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy.

Ueda-Hayakawa I, Hamaguchi Y, Okiyama N, Motegi S, Yamaoka T, Miyake S, Higashi A, Okamoto H, Takehara K, Fujimoto M.

Br J Dermatol. 2019 Apr;180(4):881-887. doi: 10.1111/bjd.17098. Epub 2018 Oct 10.

PMID:
30120913
7.

Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins.

Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, Ishiguro N, Ueda-Hayakawa I, Asano Y, Ogawa F, Fujikawa K, Miyagi T, Mabuchi E, Hirose K, Akimoto N, Hatta N, Tsutsui K, Higashi A, Igarashi A, Seishima M, Hasegawa M, Takehara K.

Arthritis Rheum. 2012 Feb;64(2):513-22. doi: 10.1002/art.33403.

8.

Oropharyngeal Dysphagia in Dermatomyositis: Associations with Clinical and Laboratory Features Including Autoantibodies.

Mugii N, Hasegawa M, Matsushita T, Hamaguchi Y, Oohata S, Okita H, Yahata T, Someya F, Inoue K, Murono S, Fujimoto M, Takehara K.

PLoS One. 2016 May 11;11(5):e0154746. doi: 10.1371/journal.pone.0154746. eCollection 2016.

9.

Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1γ Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy.

Aritomi T, Kido T, Nakano K, Satoh Y, Noguchi S, Jotatsu T, Hanaka T, Satoh M, Tanaka Y, Yatera K.

Intern Med. 2019 Feb 1;58(3):427-431. doi: 10.2169/internalmedicine.1007-18. Epub 2018 Sep 12.

10.

Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis.

Wolstencroft PW, Casciola-Rosen L, Fiorentino DF.

JAMA Dermatol. 2018 Oct 1;154(10):1199-1203. doi: 10.1001/jamadermatol.2018.2549.

PMID:
30140893
11.

Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.

Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider LG, Harris-Love MO, Levesque MC; RIM Study Group, Oddis CV.

Arthritis Rheumatol. 2014 Mar;66(3):740-9. doi: 10.1002/art.38270.

12.

Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies.

Ueki M, Kobayashi I, Takezaki S, Tozawa Y, Okura Y, Yamada M, Kuwana M, Ariga T.

Mod Rheumatol. 2019 Mar;29(2):351-356. doi: 10.1080/14397595.2018.1452353. Epub 2018 Apr 9.

PMID:
29532710
13.

Comparison of radioimmunoprecipitation versus antigen-specific assays for identification of myositis-specific autoantibodies in dermatomyositis patients.

Kang EH, Kuwana M, Okazaki Y, Lee EY, Lee YJ, Lee EB, Song YW.

Mod Rheumatol. 2014 Nov;24(6):945-8. doi: 10.3109/14397595.2014.896494. Epub 2014 Mar 26.

PMID:
24670134
14.

Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis.

Trallero-Araguás E, Rodrigo-Pendás JÁ, Selva-O'Callaghan A, Martínez-Gómez X, Bosch X, Labrador-Horrillo M, Grau-Junyent JM, Vilardell-Tarrés M.

Arthritis Rheum. 2012 Feb;64(2):523-32. doi: 10.1002/art.33379. Review.

15.

Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.

Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, Meyer A, Tohmé A, Charuel JL, Musset L, Allenbach Y, Benveniste O.

JAMA Neurol. 2018 Dec 1;75(12):1528-1537. doi: 10.1001/jamaneurol.2018.2598.

PMID:
30208379
16.

Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis.

Deakin CT, Yasin SA, Simou S, Arnold KA, Tansley SL, Betteridge ZE, McHugh NJ, Varsani H, Holton JL, Jacques TS, Pilkington CA, Nistala K, Wedderburn LR; UK Juvenile Dermatomyositis Research Group.

Arthritis Rheumatol. 2016 Nov;68(11):2806-2816. doi: 10.1002/art.39753. Epub 2016 Oct 9.

17.

A novel case of TIF1 gamma autoantibody positive dermatomyositis associated with a non-functional pancreatic neuroendocrine tumor.

Varedi D, Frigerio A, Scaife C, Hull C.

Dermatol Online J. 2019 Mar 15;25(3). pii: 13030/qt4fc9p1bd.

18.

[Comparison of clinical characteristics and laboratory parameters of patients with dermatomyositis-specific autoantibodies and autoantibody-negative patients].

Bodoki L, Budai D, Nagy-Vincze M, Griger Z, Betteridge Z, Dankó K.

Orv Hetil. 2015 Sep 6;156(36):1451-9. doi: 10.1556/650.2015.30221. Hungarian.

PMID:
26320599
19.

Polymyositis and dermatomyositis as a risk of developing cancer.

Jakubaszek M, Kwiatkowska B, Maślińska M.

Reumatologia. 2015;53(2):101-5. doi: 10.5114/reum.2015.51510. Epub 2015 May 18. Review.

20.

Case report of anti-transcription intermediary factor-1-γ/α antibody-positive dermatomyositis associated with gastric cancer and immunoglobulin G4-positive pulmonary inflammatory pseudotumor.

Ito K, Imafuku S, Hamaguchi Y, Fujimoto M, Nakayama J.

J Dermatol. 2013 Jul;40(7):567-9. doi: 10.1111/1346-8138.12141. Epub 2013 May 10.

PMID:
23663102

Supplemental Content

Support Center